慢性阻塞性肺疾病急性加重基础:诊断、治疗、预防与疾病影响
本文综述了慢阻肺急性加重(ECOPD)的诊断、治疗与预防。ECOPD是影响疾病进展、合并症、健康状况和死亡率的关键事件,也是慢阻肺社会经济负担的最大组成部分。当前定义基于呼吸道症状急性恶化需额外治疗,但需客观指标如血常规和C反应蛋白提高诊断准确性并实现个体化管理。干预有三个时间点:急性期减轻严重程度和持续时间;随后预防早期复发和再入院;长期建立预防措施降低未来风险。
要点
- ECOPD定义需额外治疗的呼吸道症状急性恶化,但需客观指标提高诊断准确性。
- 急性管理包括糖皮质激素、抗生素和无创通气等呼吸支持措施。
- 长期预防以吸入治疗为核心,双支扩剂降低加重频率,频繁加重者考虑三联治疗。
核心结论
- ECOPD是影响慢阻肺进展、合并症、健康状况和死亡率的关键事件,也是社会经济负担的最大组成部分。
- 改善ECOPD结局需在急性期、随后和长期三个时间点进行干预。
- 针对特定炎症通路的靶向治疗正在探索用于预防急性加重。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- ECOPD当前定义为需额外治疗的呼吸道症状急性恶化,但其他因素如其他呼吸疾病和非呼吸疾病(如心力衰竭、血栓栓塞)也可 contribute。
- 急性感染尤其是呼吸道病毒感染和/或污染物暴露被认为是ECOPD的主要cause。
- 急性期干预包括糖皮质激素或抗生素以及呼吸支持措施包括无创通气。
- 出院后持续高碳酸血症患者使用家庭无创通气以及肺康复可产生积极影响。
- 双支扩剂降低加重频率,持续加重患者应考虑三联治疗,尤其血嗜酸性粒细胞升高时。
关键数值与推荐
- ECOPD定义:呼吸道症状急性恶化需额外治疗。
- 长期预防:双支扩剂降低加重频率;持续加重者考虑三联治疗,尤其血嗜酸性粒细胞升高时;其他选项包括磷酸二酯酶抑制剂和大环内酯类抗生素。
临床怎么用
- 使用血常规和C反应蛋白等客观指标提高ECOPD诊断准确性并指导个体化管理。
- 急性期根据病情使用糖皮质激素、抗生素和无创通气等支持措施。
- 出院后关注早期复发和再入院预防,对持续高碳酸血症患者考虑家庭无创通气,并开展肺康复。
- 长期预防以吸入治疗为核心,频繁加重者考虑升级至三联治疗。
局限性
- 当前治疗宽泛,需更好理解临床表型和生物标志物以建立更 tailored 方法,例如抗生素处方。
- 有效抗病毒治疗尚未满足。
- 抗生素或抗炎药预防早期复发和再入院的益处尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized by an acute deterioration in respiratory symptoms, are fundamental events impacting negatively upon disease progression, comorbidities, wellbeing and mortality. ECOPD also represent the largest component of the socioeconomic burden of COPD. ECOPDs are currently defined as acute worsening of respiratory symptoms that require additional therapy. Definitions that require worsening of dyspnoea and sputum volume/purulence assume that acute infections, especially respiratory viral infections, and/or exposure to pollutants are the main cause of ECOPD. But other factors may contribute to ECOPD, such as the exacerbation of other respiratory diseases and non-respiratory diseases (e.g., heart failure, thromboembolism). The complexity of worsening dyspnoea has suggested a need to improve the definition of ECOPD using objective measurements such as blood counts and C-reactive protein to improve accuracy of diagnosis and a personalized approach to management. There are three time points when we can intervene to improve outcomes: acutely, to attenuate the length and severity of an established exacerbation; in the aftermath, to prevent early recurrence and readmission, which are common, and in the long-term, establishing preventative measures that reduce the risk of future events. Acute management includes interventions such as corticosteroids or antibiotics and measures to support the respiratory system, including non-invasive ventilation (NIV). Current therapies are broad and better understanding of clinical phenotypes and biomarkers may help to establish a more tailored approach, for example in relation to antibiotic prescription. Other unmet needs include effective treatment for viruses, which commonly cause exacerbations. Preventing early recurrence and readmission to hospital is important and the benefits of interventions such as antibiotics or anti-inflammatories in this period are not established. Domiciliary NIV in those patients who are persistently hypercapnic following discharge and pulmonary rehabilitation can have a positive impact. For long-term prevention, inhaled therapy is key. Dual bronchodilators reduce exacerbation frequency but in patients with continuing exacerbations, triple therapy should be considered, especially if blood eosinophils are elevated. Other options include phosphodiesterase inhibitors and macrolide antibiotics. ECOPD are a key component of the assessment of COPD severity and future outcomes (quality of life, hospitalisations, health care resource utilization, mortality) and are a central component in pharmacological management decisions. Targeted therapies directed towards specific pathways of inflammation are being explored in exacerbation prevention, and this is a promising avenue for future research.
引用
- MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology. 2021. PMID: 33893708. doi:10.1111/resp.14041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。